Skip to main content

Table 1 Comparison of data obtained at baseline and after 3–6 months of follow up in all three groups of patients

From: The effectiveness of lixisenatide as an add on therapy to basal insulin in diabetic type 2 patients previously treated with different insulin regimes: a multi-center observational study

Type of insulin regime (n) Parameters Baseline Control visit p value
Mean ± SD Mean ± SD
Premix (50) Weight (kg) 104 ± 14 99 ± 13  0.003
BMI (kg/m2) 38.1 ± 3.1 36.0 ± 3.1  0.039
Total daily insulin (IU) 53 ± 21 41 ± 12 < 0.001
Hba1c (%) 8.4 ± 1.2 7.6 ± 0.9 < 0.001
FBG (mmol/l) 10.1 ± 2.4 7.7 ± 1.8 < 0.001
PPG (mmol/l) 10.8 ± 2.5 8.7 ± 2 < 0.001
Basal oral (46) Weight (kg) 109 ± 12 104 ± 11  0.003
BMI (kg/m2) 38.7 ± 3.3 38.6 ± 10 NS
Total daily insulin (IU) 35 ± 14 37 ± 11 NS
Hba1c (%) 8.5 ± 0.9 7.6 ± 0.7 < 0.001
FBG (mmol/l) 8.3 ± 2.4 7.2 ± 1.6  0.009
PPG (mmol/l) 11.4 ± 2.1 8.4 ± 1.7 < 0.001
Basal bolus (15) Weight (kg) 107 ± 19 98 ± 14 < 0.001
BMI (kg/m2) 36.0 ± 1 33.8 ± 1.1  0.039
Total daily insulin (IU) 71 ± 27 50 ± 24  0.006
Hba1c (%) 9.6 ± 1.8 7.5 ± 0.9 < 0.001
FBG (mmol/l) 10.3 ± 3 7.6 ± 1.4 < 0.001
PPG (mmol/l) 12.4 ± 2.9 9.2 ± 2.5 < 0.001
  1. BMI body mass index, FPG fasting plasma glucose, PPG postprandial plasma glucose